Impax Launches Generic Solaraze - Analyst Blog

By
A A A

Impax Laboratories, Inc. ( IPXL ) announced the launch of its generic version of Fougera Pharmaceuticals Inc.'s (now a wholly owned subsidiary of  Novartis ( NVS )) Solaraze gel. Fougera was acquired by Novartis' generic arm, Sandoz in Jul 2012. Solaraze gel is approved for the topical treatment of actinic keratoses (AKs).

We note that in Jun 2012, Impax entered into a development, supply and distribution deal with TOLMAR, Inc. Under the agreement, TOLMAR gave Impax an exclusive license to commercialize generic Solaraze in the U.S. TOLMAR will develop and manufacture the drug.

TOLMAR was the first company to file a substantially complete abbreviated new drug application (ANDA) containing a Paragraph IV certification and was the first to obtain approval in the U.S. The patent will expire in Aug 2015. On Oct 30, 2013, the U.S. Food and Drug Administration (FDA) granted final approval for the generic Solaraze gel. 


According to IMS Health, Solaraze generated revenues of approximately $78 million in the 12 months ending Sep 2013 from the U.S.

We note that Global Pharmaceuticals, the generic unit of Impax performed impressively in the third quarter of 2013. Segmental revenues climbed 15.3% to $115.7 million during the quarter aided by the sales of new generic products launched this year. Growth was partially offset by lower sales of Impax' authorized generic version of Shire's ( SHPG ) attention deficit hyperactivity disorder (ADHD) drug, Adderall XR.

Impax currently carries a Zacks Rank #1 (Strong Buy). Investors may also consider Actelion Ltd. ( ALIOF ) which carries a Zacks Rank #1.



ACTELION LTD (ALIOF): Get Free Report

IMPAX LABORATRS (IPXL): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ADHD , ALIOF , ANDA , IPXL , NVS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com